Aberrant promoter methylation of caveolin-1 is associated with favorable response to taxane-platinum combination chemotherapy in advanced NSCLC.

Aberrant promoter methylation of caveolin-1 is associated with favorable response to taxane-platinum combination chemotherapy in advanced NSCLC.

Aberrant promoter DNA methylation can serve as a predictive biomarker for improved clinical responses to certain chemotherapeutics. One of the major advantages of methylation biomarkers is the ease of detection and clinical application. In order to identify methylation biomarkers predictive of a res...

Full description

Bibliographic Details
Main Authors:	Seth A Brodie, Courtney Lombardo, Ge Li, Jeanne Kowalski, Khanjan Gandhi, Shaojin You, Fadlo R Khuri, Adam Marcus, Paula M Vertino, Johann C Brandes
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4164573?pdf=render

Similar Items

Desensitization in patients with hypersensitivity to platinum and taxane in gynecological cancers
by: Tibor A. Zwimpfer, et al.
Published: (2024-01-01)

Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes
by: Matvey Mihajlovich Tsyganov, et al.
Published: (2022-12-01)

Registered report: Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis
by: Steven Fiering, et al.
Published: (2015-07-01)

Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy
by: Alex Molassiotis, et al.
Published: (2019-06-01)

Prostaglandin E2 Exposure Disrupts E-Cadherin/Caveolin-1-Mediated Tumor Suppression to Favor Caveolin-1-Enhanced Migration, Invasion, and Metastasis in Melanoma Models
by: Lorena Lobos-González, et al.
Published: (2023-11-01)

Caveolin-3 and Caveolin-1 Interaction Decreases Channel Dysfunction Due to Caveolin-3 Mutations
by: Patrizia Benzoni, et al.
Published: (2024-01-01)

Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients
by: Felisiak-Golabek Anna, et al.
Published: (2011-11-01)

Establishment and Genetic Profiling of Platinum/Taxane Doublet-Resistant Cells Generated by Hybridizing Single Resistant Cells
by: Seiji Isonishi, et al.
Published: (2022-09-01)

Comparison of Efficacy and Safety of Taxanes Plus Platinum and Fluorouracil Plus Platinum in the First-Line Treatment of Esophageal Cancer: A Systematic Review and Meta-Analysis
by: Yue Zhao, et al.
Published: (2022-09-01)

Mechanisms of Taxane Resistance
by: Sara M. Maloney, et al.
Published: (2020-11-01)

Caveolin-1, caveolin-3 and VEGF expression in the masticatory muscles of mdx mice
by: Alexander Spassov, et al.
Published: (2011-07-01)

Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer
by: Shirin Kianersi, et al.
Published: (2023-01-01)

Sex Differences in Taxane Toxicities
by: Nicole N. Chmielewski, et al.
Published: (2022-07-01)

Synthesis of taxane cyclization precursors
by: Chang, Edcon
Published: (2008)

Occult lymph node metastasis is not a favorable factor for resected NSCLC patients
by: Jing-Sheng Cai, et al.
Published: (2023-09-01)

Taxane diterpenes .2. Synthesis of the 7-deoxy ABC taxane skeleton, and reactions of the A-ring
by: Magnus, P, et al.
Published: (1996)

Real-world use of first-line pembrolizumab + platinum + taxane combination regimens in recurrent / metastatic head and neck squamous cell carcinoma
by: Christopher M. Black, et al.
Published: (2024-02-01)

Combination chemotherapy with taxane and platinum in patients with salivary gland carcinoma: a retrospective study of docetaxel plus cisplatin and paclitaxel plus carboplatin
by: Ryutaro Onaga, et al.
Published: (2023-06-01)

Structural insight into the stabilization of microtubules by taxanes
by: Andrea E Prota, et al.
Published: (2023-03-01)

Management of Patients with Hypersensitivity to Platinum Salts and Taxane in Gynecological Cancers: A Cross-Sectional Study by the European Network of Young Gynaecologic Oncologists (ENYGO)
by: Tibor A. Zwimpfer, et al.
Published: (2024-03-01)

Plasma exosomal APE1 expression of NSCLC patients is related to the sensitivity of platinum chemotherapy
by: ZHAO Xiao-long, DAI Xiao-yan, MAO Cheng-yi, XIAO Hua-liang, WANG Dong, DAI Nan
Published: (2021-02-01)

Editorial: Caveolins in inflammation, infections, and disease
by: Stanley Hoffman, et al.
Published: (2024-03-01)

Caveolae and caveolins role in health and disease
by: R. I. Voroblev, et al.
Published: (2008-12-01)

Involvement of caveolin-1 in skin diseases
by: Naoko Takamura, et al.
Published: (2022-11-01)

RB1 aberrations predict outcomes of immune checkpoint inhibitor combination therapy in NSCLC
by: Qian Wang, et al.
Published: (2023-06-01)

Upfront Taxane Could Be Superior to Pegylated Liposomal Doxorubicin (PLD): A Retrospective Real-World Analysis of Treatment Sequence Taxane–PLD versus PLD–Taxane in Patients with Metastatic Breast Cancer
by: Till Wallrabenstein, et al.
Published: (2023-10-01)

Caveolin-1 and lipid rafts in confluent BeWo trophoblasts: evidence for Rock-1 association with caveolin-1.
by: Rashid-Doubell, F, et al.
Published: (2007)

Caveolin-1 Expression Increases upon Maturation in Dendritic Cells and Promotes Their Migration to Lymph Nodes Thereby Favoring the Induction of CD8+ T Cell Responses
by: Cesar Oyarce, et al.
Published: (2017-12-01)

Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations
by: Wenjing Zhang, et al.
Published: (2022-06-01)

Bevacizumab Combined with Platinum–Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients
by: Jalid Sehouli, et al.
Published: (2021-09-01)

Chromosomal instability, colorectal cancer and taxane resistance.
by: Swanton, C, et al.
Published: (2006)

Cell death in cancer chemotherapy using taxanes
by: Ana P. Xu, et al.
Published: (2024-01-01)

Supplemental Preparations in Taxane-Induced Neuropathy Management
by: AmirHosein Sanei, et al.
Published: (2023-04-01)

Taxanes in adjuvant and neoadjuvant therapy for breast cancer
by: S. V. Limareva
Published: (2014-08-01)

Efforts toward the synthesis of taxane natural products
by: Mahaney, Paige E. (Paige Erin)
Published: (2007)

TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
by: T. N. Skvortsova, et al.
Published: (2017-01-01)

The prognostic role of the class III β-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis.
by: Yan-Long Yang, et al.
Published: (2014-01-01)

Regulation of trophoblast differentiation and fusion by Caveolin-1
by: Collent, G, et al.
Published: (2008)

Engineering caveolin-mediated endocytosis in Saccharomyces cerevisiae
by: Qian Zhang, et al.
Published: (2022-12-01)

Caveolin-3 and Arrhythmias: Insights into the Molecular Mechanisms
by: Miaomiao He, et al.
Published: (2022-03-01)